Parithera SA

Parithera SA specializes in the development of a platform for the clinical single cell sequencing of rare cells. Paritheras breakthrough technologies enable the development of the first walk-away instrument for cancer cell extraction from blood samples and their preparation for single-cell sequencing analysis. Thanks to the simplified workflow and increased robustness, the ExTrace is the first solution which can be deployed at scale. Parithera will serve the biopharma development market ($1-2 Bn for the liquid biopsy segment in the US, source: Cowen and Company) and CDx/IVD markets ($22-80 Bn in the US, source Cowen and Company).